PARNAXLABParnax Lab Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic products; herbal products; and nutraceutical products. It also provides Oral Formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provides drug identification and development services; in- and out-licensing services; and contract research and manufacturing services The company was formerly known as Krishna-Deep Trade & Investments Limited and changed its name to Parnax Lab Limited in April 2012. The company was incorporated in 1982 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on PARNAXLAB — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.87
- • Promoter holding: 85.3%
- • Valuation vs sector: P/E 16.3 vs sector 40.5
- • Distance from 52-week high: 15.1% below high
- • Volume trend: 1.6x baseline
- • Sector momentum: sector +6.2% (1m)
Bull case
- • Debt/Equity: 0.87
- • Promoter holding: 85.3%
- • Valuation vs sector: P/E 16.3 vs sector 40.5
- • Distance from 52-week high: 15.1% below high
Bear case
- • Recently listed — limited trading history, scores are provisional
- • Revenue growth: 6.4% YoY
- • Profit growth: -87.0% YoY
- • Insufficient price history
Key risks
- • Recently listed — limited trading history, scores are provisional
- • Revenue growth: 6.4% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹11.59). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.